Abcam, a Cambridge, UK-based provider of antibody microarrays, this week announced a series of management changes.
Alan Hirzel has been appointed CEO, succeeding Jonathan Milner. Hirzel previously was chief markeing officer at Abcam and has served on its board since January. Milner will continue to serve as deputy chairman of Abcam's board and remains the company's largest shareholder.
Abcam also said this week that Peter Keen will not seek re-election to the company's board. Keen has sat on Abcam's board since 2005, where he was chairman of the remuneration and audit committees, as well as senior independent director. Abcam said that Louise Patten will assume the senior independent director role following the company's annual general meeting in November.